Although these studies were not designed to investigate the activity according to NSCLC histologies or EMT status, these results suggest rational strategy to enrich for lung cancer patients that might benefit from treatment with anti-IGF-1R antibodies. The gene discussed is IGF1R; the disease is non-small cell lung carcinoma.